Zaragoza V, Pérez A, Sánchez J L, Oliver V, Martínez L, Alegre V
Servicio de Dermatología, Consorcio Hospital General Universitario de Valencia, Valencia, España.
Actas Dermosifiliogr. 2010 Jan-Feb;101(1):47-53.
Clinical experience has shown that, in patients with psoriasis, suspending treatment with etanercept at week 24, as indicated in the prescribing information, may lead to a rebound effect. Several clinical trials support long-term use of etanercept, which was shown to have a good safety and efficacy profile.
This was a retrospective, observational study of 43 patients with moderate to severe plaque psoriasis, with and without joint involvement, who received continuous treatment with etanercept for more than 24 weeks.
Etanercept was administered for a mean of 57 weeks. Overall, the Psoriasis Area and Severity Index (PASI) score decreased from a baseline value of 22.5 to 4.3 after treatment. In addition, with continuous treatment, most patients maintained decreases in PASI scores of 50% and even of 75%. Some patients without significant improvement in their PASI score in the first 24 weeks did manage to achieve significant results after prolonged treatment. These outcomes were achieved with a low incidence of adverse effects (reported in 13 patients [30.2%]), which were generally mild.
We present our clinical experience with long-term etanercept treatment in patients with moderate to severe psoriasis, with and without associated joint involvement. The efficacy and safety profiles were found to be favorable.
临床经验表明，对于银屑病患者，按照处方信息在第24周停用依那西普治疗可能会导致反跳效应。多项临床试验支持依那西普的长期使用，其安全性和有效性良好。
这是一项回顾性观察研究，纳入了43例中度至重度斑块状银屑病患者，无论是否有关节受累，均接受依那西普持续治疗超过24周。
依那西普的平均使用时间为57周。总体而言，治疗后银屑病面积和严重程度指数（PASI）评分从基线值22.5降至4.3。此外，随着持续治疗，大多数患者的PASI评分保持降低50%甚至75%。一些在最初24周PASI评分无显著改善的患者在长期治疗后确实取得了显著效果。这些结果是在不良反应发生率较低（13例患者[30.2%]报告）的情况下实现的，且不良反应通常较轻。
我们展示了在中度至重度银屑病患者（无论是否伴有关节受累）中使用依那西普进行长期治疗的临床经验。发现其疗效和安全性良好。
